SG11201602268XA - Compound for activating ampk and uses thereof - Google Patents

Compound for activating ampk and uses thereof

Info

Publication number
SG11201602268XA
SG11201602268XA SG11201602268XA SG11201602268XA SG11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA
Authority
SG
Singapore
Prior art keywords
compound
activating ampk
ampk
activating
Prior art date
Application number
SG11201602268XA
Other languages
English (en)
Inventor
Jen-Yi Chio
Han-Min Chen
Cheng-Yi Kuo
Jiun-Tsai Lin
Chun-Fang Huang
Original Assignee
Energenesis Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Energenesis Biomedical Co Ltd filed Critical Energenesis Biomedical Co Ltd
Publication of SG11201602268XA publication Critical patent/SG11201602268XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201602268XA 2013-09-26 2013-09-26 Compound for activating ampk and uses thereof SG11201602268XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/084294 WO2015042821A1 (fr) 2013-09-26 2013-09-26 Composé servant à l'activation de l'ampk et ses utilisations

Publications (1)

Publication Number Publication Date
SG11201602268XA true SG11201602268XA (en) 2016-04-28

Family

ID=52741776

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602268XA SG11201602268XA (en) 2013-09-26 2013-09-26 Compound for activating ampk and uses thereof

Country Status (12)

Country Link
EP (2) EP3050567B1 (fr)
JP (1) JP6254263B2 (fr)
KR (3) KR102221723B1 (fr)
AU (3) AU2013401767B2 (fr)
CA (4) CA3112108C (fr)
DK (1) DK3050567T3 (fr)
ES (1) ES2863173T3 (fr)
IL (1) IL244752B (fr)
MY (1) MY182801A (fr)
PL (1) PL3050567T3 (fr)
SG (1) SG11201602268XA (fr)
WO (1) WO2015042821A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937036A (zh) * 2016-10-21 2019-06-25 赛威蒂斯株式会社 包含米多君或其药学上可接受的盐作为有效成分的糖尿病及/或高血脂症的预防或治疗用药学组合物
JP7185226B2 (ja) * 2018-11-22 2022-12-07 国立大学法人 鹿児島大学 １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤
KR102145438B1 (ko) * 2018-12-21 2020-08-18 연세대학교 산학협력단 퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO60784A2 (fr) * 1972-11-03 1976-07-15
EP0599987A4 (fr) * 1991-08-23 1995-02-01 Gensia Inc Procede servant a abaisser les taux de lipides sanguins.
US6342484B1 (en) * 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
JP3580900B2 (ja) * 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 α−グルコシダーゼ阻害剤を含む糖を主体とする組成物を有効成分とする食品及び飼料
JPH1135468A (ja) * 1997-07-17 1999-02-09 Meiji Milk Prod Co Ltd 核酸とその成分を用いたｉ型アレルギー 抑制食品及び抑制剤
EP1302196A1 (fr) * 2001-10-16 2003-04-16 Habinger, René, Ing. Mag. Dentifrice pour promouvoir l'intelligence
EP1665940A4 (fr) * 2003-09-02 2011-01-19 Bbk Bio Corp Denree alimentaire dietetique
US20070254853A1 (en) * 2006-05-01 2007-11-01 Board Of Regents, The University Of Texas System Compositions and Methods for Promotion of Wound Healing
US8165819B2 (en) * 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
WO2009014642A1 (fr) * 2007-07-19 2009-01-29 Amgen Inc. Combinaisons pour le traitement du cancer
US20090131537A1 (en) * 2007-11-14 2009-05-21 Wille Jr John Jacob Wound healing compositions
WO2010002492A1 (fr) * 2008-04-29 2010-01-07 University Of Chicago Procédés d’utilisation de dérivés d’adénine pour le traitement du diabète et d’autres troubles
CN101433540A (zh) * 2008-12-02 2009-05-20 中山大学 3-甲基腺嘌呤在制备用于治疗神经退行性疾病的药物中的应用
CN101744191A (zh) * 2008-12-03 2010-06-23 许玉宝 一种南瓜粉丝
US20130116215A1 (en) * 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用

Also Published As

Publication number Publication date
PL3050567T3 (pl) 2021-06-14
CA3112089C (fr) 2023-04-04
AU2013401767B2 (en) 2019-05-09
EP3050567B1 (fr) 2020-11-04
KR20160060137A (ko) 2016-05-27
AU2019203668B2 (en) 2020-09-10
CA3112089A1 (fr) 2015-04-02
KR102101465B1 (ko) 2020-04-17
CA3112108C (fr) 2023-09-12
IL244752B (en) 2020-01-30
AU2020244377B2 (en) 2022-04-07
ES2863173T3 (es) 2021-10-08
KR20200041393A (ko) 2020-04-21
MY182801A (en) 2021-02-05
DK3050567T3 (da) 2021-02-08
WO2015042821A1 (fr) 2015-04-02
AU2019203668A1 (en) 2019-06-13
EP3769766A1 (fr) 2021-01-27
EP3050567A4 (fr) 2017-04-05
CA3112108A1 (fr) 2015-04-02
CA2925511C (fr) 2021-05-04
JP6254263B2 (ja) 2017-12-27
KR102221723B1 (ko) 2021-03-03
KR102248806B1 (ko) 2021-05-10
KR20200041392A (ko) 2020-04-21
AU2013401767A1 (en) 2016-04-21
IL244752A0 (en) 2016-04-21
EP3050567A1 (fr) 2016-08-03
CA3112114C (fr) 2023-03-28
CA3112114A1 (fr) 2015-04-02
CA2925511A1 (fr) 2015-04-02
AU2020244377A1 (en) 2020-10-29
JP2016531855A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and their uses
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HK1223351A1 (zh) 嘧啶衍生物作為激酶抑制劑
ZA201602220B (en) Heterocyclic compounds and uses thereof
HRP20180635T1 (hr) Pirazolamidni spoj i njegova upotreba u medicini
HK1219276A1 (zh) 二雜芳基化合物及其用途
GB201323008D0 (en) Compounds and uses thereof
GB201300707D0 (en) Compounds and processes
GB201307233D0 (en) Compounds and uses thereof
IL244752B (en) ampk activating compound and uses for it
GB201309180D0 (en) Compounds and Their Uses
HK1223307A1 (zh) 新型化合物和其用途
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201323005D0 (en) Compounds and uses thereof
GB201320161D0 (en) Compounds and their uses
GB201307201D0 (en) New compounds and uses
GB201307202D0 (en) New compounds and uses
GB201301734D0 (en) New compounds and uses
GB201309248D0 (en) Compounds and combinations